Tsubota Laboratory Past Earnings Performance
Past criteria checks 0/6
Tsubota Laboratory's earnings have been declining at an average annual rate of -66.3%, while the Pharmaceuticals industry saw earnings growing at 5.6% annually. Revenues have been declining at an average rate of 10.5% per year.
Key information
-66.3%
Earnings growth rate
-66.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 3.4% |
| Revenue growth rate | -10.5% |
| Return on equity | -46.9% |
| Net Margin | -95.2% |
| Next Earnings Update | 13 Aug 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Tsubota Laboratory makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 673 | -641 | 670 | 0 |
| 31 Dec 23 | 246 | -1,066 | 494 | 126 |
| 30 Sep 23 | 448 | -277 | 473 | 126 |
| 30 Jun 23 | 750 | 24 | 446 | 126 |
| 31 Mar 23 | 954 | 90 | 394 | 126 |
| 31 Dec 22 | 972 | 139 | 368 | 116 |
| 31 Mar 22 | 640 | 153 | 276 | 116 |
| 31 Mar 21 | 687 | 201 | 356 | 0 |
| 31 Mar 20 | 441 | 3 | 262 | 0 |
Quality Earnings: 4890 is currently unprofitable.
Growing Profit Margin: 4890 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4890 is unprofitable, and losses have increased over the past 5 years at a rate of 66.3% per year.
Accelerating Growth: Unable to compare 4890's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4890 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (13.3%).
Return on Equity
High ROE: 4890 has a negative Return on Equity (-46.89%), as it is currently unprofitable.